These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 28323967)

  • 21. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension.
    Leiter LA; Cefalu WT; de Bruin TW; Gause-Nilsson I; Sugg J; Parikh SJ
    J Am Geriatr Soc; 2014 Jul; 62(7):1252-62. PubMed ID: 24890683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
    Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
    Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
    Bolinder J; Ljunggren Ö; Kullberg J; Johansson L; Wilding J; Langkilde AM; Sugg J; Parikh S
    J Clin Endocrinol Metab; 2012 Mar; 97(3):1020-31. PubMed ID: 22238392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular and Renal Morbidity in Takayasu Arteritis: A Population-Based Retrospective Cohort Study From the United Kingdom.
    Goel R; Chandan JS; Thayakaran R; Adderley NJ; Nirantharakumar K; Harper L
    Arthritis Rheumatol; 2021 Mar; 73(3):504-511. PubMed ID: 32969145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial.
    Natali A; Nesti L; Fabiani I; Calogero E; Di Bello V
    Cardiovasc Diabetol; 2017 Oct; 16(1):130. PubMed ID: 29025406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study.
    Tang Y; Sun Q; Bai XY; Zhou YF; Zhou QL; Zhang M
    Nutr Diabetes; 2019 Nov; 9(1):32. PubMed ID: 31685792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial.
    Singh JSS; Mordi IR; Vickneson K; Fathi A; Donnan PT; Mohan M; Choy AMJ; Gandy S; George J; Khan F; Pearson ER; Houston JG; Struthers AD; Lang CC
    Diabetes Care; 2020 Jun; 43(6):1356-1359. PubMed ID: 32245746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
    Hohendorff J; Szopa M; Skupien J; Kapusta M; Zapala B; Platek T; Mrozinska S; Parpan T; Glodzik W; Ludwig-Galezowska A; Kiec-Wilk B; Klupa T; Malecki MT
    Endocrine; 2017 Aug; 57(2):272-279. PubMed ID: 28593615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dapagliflozin combination therapy in type 2 diabetes mellitus.
    Yacoub T
    Postgrad Med; 2016 Jan; 128(1):124-36. PubMed ID: 26571022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
    Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V
    Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus.
    Shao H; Zhai S; Zou D; Mir MU; Zawadzki NK; Shi Q; Liu S; Shi L
    Curr Med Res Opin; 2017 Feb; 33(2):359-369. PubMed ID: 27817216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
    Berg DD; Wiviott SD; Scirica BM; Gurmu Y; Mosenzon O; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Johanson P; Johansson PA; Langkilde AM; Raz I; Braunwald E; Sabatine MS
    Circulation; 2019 Nov; 140(19):1569-1577. PubMed ID: 31474116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
    Wiviott SD; Raz I; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Silverman MG; Bansilal S; Bhatt DL; Leiter LA; McGuire DK; Wilding JP; Gause-Nilsson IA; Langkilde AM; Johansson PA; Sabatine MS
    Am Heart J; 2018 Jun; 200():83-89. PubMed ID: 29898853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels.
    Bays HE; Sartipy P; Xu J; Sjöström CD; Underberg JA
    J Clin Lipidol; 2017; 11(2):450-458.e1. PubMed ID: 28502502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C; Tentolouris N; Kourlaba G; Maniadakis N
    Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial.
    Monteiro P; Bergenstal RM; Toural E; Inzucchi SE; Zinman B; Hantel S; Kiš SG; Kaspers S; George JT; Fitchett D
    Age Ageing; 2019 Nov; 48(6):859-866. PubMed ID: 31579904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients.
    Fung CS; Wan EY; Wong CK; Jiao F; Chan AK
    Cardiovasc Diabetol; 2015 Oct; 14():137. PubMed ID: 26453464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin.
    Grandy S; Hashemi M; Langkilde AM; Parikh S; Sjöström CD
    Diabetes Obes Metab; 2014 Jul; 16(7):645-50. PubMed ID: 24443876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.
    Fioretto P; Mansfield TA; Ptaszynska A; Yavin Y; Johnsson E; Parikh S
    Drugs Aging; 2016 Jul; 33(7):511-22. PubMed ID: 27357173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.